ATTAIN-1

ATTAIN-1 is the phase 3 trial that put an oral GLP-1 pill on the same shelf as the weekly injections. It enrolled 3,127 adults who had obesity but not diabetes and randomized them to once-daily orforglipron at three dose levels or to placebo, alongside diet and physical activity advice, for 72 weeks. Results were published in the New England Journal of Medicine in November 2025.

The headline number: at the highest dose studied, average body weight fell 11.2% from baseline versus 2.1% on placebo. For someone starting at 220 pounds, that average is roughly 25 pounds. Beyond the average, 54.6% of people on the top dose lost at least 10% of their starting weight, 36.0% lost at least 15%, and 18.4% lost at least 20% — compared with 12.9%, 5.9% and 2.8% on placebo. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved too.

The side-effect story was familiar: mostly mild-to-moderate gastrointestinal complaints, with 5.3% to 10.3% of people in the orforglipron groups stopping treatment because of adverse events versus 2.7% on placebo. That is the same nausea-and-titration pattern anyone on an injectable GLP-1 would recognize.

ATTAIN-1 supported the approval of Foundayo, whose label sets a dose ladder starting at 0.8 mg once daily and stepping up no faster than every 30 days through 2.5, 5.5, 9, 14.5 and a maximum of 17.2 mg. The common confusion is comparing the trial’s milligram labels with the prescription bottle and assuming a mismatch; read the ladder on the label, not the trial abstract. The other frequent mix-up is expecting injection-grade results — ATTAIN-1’s average sits below what SURMOUNT-1 reported for tirzepatide, and the honest framing is convenience versus magnitude.

Worth asking your clinician: whether a daily pill fits your routine better than a weekly shot, how the titration schedule maps onto your calendar, and what the plan is if you stall mid-ladder. Our Foundayo titration cheat sheet lays the steps out.